ArticleFrontiers in endocrinology2026
Association of remnant cholesterol with cardiovascular events and mortality in biopsy-proven diabetic kidney disease.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Remnant cholesterol (RC) has been recognized as a critical risk factor for vascular diseases. However, its association with cardiovascular disease (CVD) and overall mortality in individuals with diabetic kidney disease (DKD) has not been thoroughly investigated. Methods: This retrospective single-center study enrolled 329 patients with biopsy-confirmed DKD from August 2009 to December 2018. The prognosis of patients with varying RC levels was compared. In addition, the association between RC levels and left ventricular structure and function was examined. Furthermore, the predictive capability of RC for clinical outcomes was assessed. Results: Over the follow-up period, 76 patients (23.1%) experienced CVD events, while 44 patients (13.4%) died. Kaplan-Meier analysis demonstrated that patients in the high RC group exhibited significantly elevated rates of CVD events ( Conclusion: RC independently contributes to the risk of CVD events and all-cause mortality in individuals with biopsy-confirmed DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.